Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698857 | 1.00 | POLA1 (0.58) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6698854 | 1.00 | POLA1 (0.58) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6702310 | 0.92 | POLA1 (0.48) | POLA1KCNH2ALDH1A1RXFP1TSHR | |
| SCHEMBL6697003 | 0.92 | POLA1 (0.48) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6697611 | 0.92 | POLA1 (0.60) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6703845 | 0.91 | POLA1 (0.62) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6700074 | 0.89 | POLA1 (0.59) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6703911 | 0.88 | POLA1 (0.58) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6697437 | 0.88 | POLA1 (0.61) | POLA1KCNH2MEN1KMT2AF2 | |
| SCHEMBL6698326 | 0.87 | POLA1 (0.60) | POLA1KCNH2MEN1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | claimed |
| EP-1299395-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-6673793-B2 | N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY | PHARMACIA & UPJOHN CO. | 2004-01-06 | — | — | US | claimed |
| EP-1299395-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | claimed |
| WO-2002004462-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | POLA1 2550/4885KCNH2 4383/4885MEN1 3030/4885 |
| US-20020103170-A1 | Oxazinoquinolones useful for the treatment of viral infections | ZC3HAV1, RPL5, ZC3HAV1L | POLA1 111/4885KCNH2 964/4885MEN1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.